Quarterly ResultMay 14, 2026, 08:47 AM
Senti Bio: Positive FDA Feedback for SENTI-202 Pivotal Trial; $40M Financing
AI Summary
Senti Biosciences reported its first quarter 2026 financial results, alongside significant business updates. The company received positive FDA feedback supporting a single-arm pivotal trial for potential registration of SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Senti Bio also secured a strategic financing vehicle for up to $40 million in senior secured convertible notes, with an initial $10 million tranche expected in May. Operational streamlining contributed to a substantially reduced quarterly net loss of $4.2 million and a lower cash burn of $7.5 million.
Key Highlights
- Positive FDA feedback supports a single-arm pivotal trial for SENTI-202 in R/R AML.
- Secured strategic financing vehicle for up to $40 million in senior secured convertible notes.
- Initial $10 million tranche of financing expected to close in May 2026.
- Net loss significantly reduced to $4.2 million in Q1 2026 from $14.1 million in Q1 2025.
- Net cash used in operating activities decreased to $7.5 million in Q1 2026 from $14.1 million in Q1 2025.
- Research and development expenses decreased to $5.3 million in Q1 2026 from $9.3 million in Q1 2025.
- Cash and cash equivalents were $8.9 million as of March 31, 2026.
- Recognized a $6.9 million gain from lease modification during the quarter.